Navigation Links
BioSpecifics Technologies Corp. Announces Initiation of Phase 2b Trial of CCH for Treatment of Frozen Shoulder Syndrome
Date:12/13/2013

contracture, and Peyronie's disease pending applicable regulatory approvals. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome in a Phase 2b study and also for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase 2 trials, and expects to report top-line data from these trials in the fourth quarter of 2013. For more information, please visit www.biospecifics.com.

Forward-Looking Statements

This release includes "forward-looking statements" within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are "forward-looking statements." The forward-looking statements include statements concerning, among other things, the design, efficacy, safety and timing of the Phase 2b study for CCH for the potential treatment of FSS; whether CCH will be approved by the FDA and, if approved, whether it will be an effective or successful treatment option for FSS; if approved, whether CCH for the potential treatment of FSS will allow quicker relief for patients; and the potential for the use of CCH with other indications, including, uterine fibroids, canine and human lipoma;  In some cases, these statements can be identified by forward-looking words such as "believe," "expect," "anticipate," "plan," "estimate," "likely," "may," "will," "could," "continue," "project," "predict," "goal," the negative or plural of these words, and other similar expressions. These forward-looking statements are predictions based on BioSpecifics' current expectations and its projections about future events. There are a number of important factors that could cause BioSpecifics' actual results to differ materially from thos
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
11. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... NEW YORK, Feb. 2, 2011 Reportlinker.com announces that ... catalogue: US Prebiotics Industry ... report analyzes the US And European markets for Prebiotics ... is further analyzed by the following product segments: Mannan-Oligosaccharide ...
... Feb. 2, 2011 H. D. Smith recently announced ... strategic planning and business development, Robert Appleby to corporate ... vice president marketing.  These appointments are the latest organizational ... address evolving customer needs. Joseph ...
Cached Medicine Technology:US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7H. D. Smith Aligns Leadership Positions to Fill Three Senior Roles 2
(Date:8/4/2015)... ... 04, 2015 , ... In the most recent talcum powder ... report that a new location for pretrial proceedings is under consideration, according to ... warning information at their website, the Talcum Powder Cancer Lawsuit Center. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA ... which spotlights treating depression. Depression affects millions of Americans every single year. To ... inform and enlighten viewers with the latest segment produced with the assistance of ...
(Date:8/3/2015)... , ... August 04, 2015 , ... ... Armethia Holt as a 2015-2016 inductee into the NAPW VIP Woman of ... healthcare. With more than 700,000 members and over 200 operating Local Chapters, NAPW ...
(Date:8/3/2015)... ... ... offers the most affordable web design and SEO services for start up companies. Every ... dollar. Every company that is starting out needs to be online in this technology ... a start up need to be online, they need to physically be present and visible ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Since 1978, the ... declined, according to a new publication released today by the AAMC (Association of American ... college graduates over the past three decades, the number of black male applicants to ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:National Association of Professional Women Inducts Armethia Holt, CEO at AA&G Group Homes, LLC, Into its VIP Woman of the Year Circle 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... In a follow-up study, researchers at Moffitt Cancer Center and ... cancer might experience prolonged fatigue years after their therapy. The ... of CANCER , is a follow-up to a study ... researchers published in CANCER in 2007. "Fatigue ...
... , MONDAY, Dec. 5 (HealthDay News) --,Hospitalized patients ... most common cause of infectious diarrhea in hospitals -- will ... new study indicates. Experts say prevention is key to ... C. difficile . For the study, published Dec. 5 ...
... News) -- Teenagers with autism who also have epilepsy ... The combination means that certain behaviors common among ... front of their faces -- could increase their risk ... to 14 percent of children with epilepsy, the rate ...
... By Alan Mozes HealthDay Reporter , SUNDAY, Dec. ... to face an increased risk for seizures while watching 3-D ... did reveal that about one in five of these children ... including nausea, headaches and dizziness. "Normal people have a ...
... University of New Hampshire Crimes against Children Research Center suggest ... found the percentage of youth who send nude pictures of ... The other found that when teen sexting images do come ... like sex offenders. The studies were carried out by ...
... Barcelona, 1st December, 2011.- A study by researchers Ral ... in Biomedicine (IRB Barcelona) and Pilar Navarro at the ... a new reprogramming mechanism for the expression of genes ... cell. In the study, published in this week,s edition ...
Cached Medicine News:Health News:Follow-up study finds prolonged fatigue for those who had chemotherapy for breast cancer 2Health News:Common Hospital Infection Lengthens Patient Stays 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 3Health News:Concerns about teen sexting overblown, according to new UNH research 2Health News:Discovery of a new reprogramming mechanism for tumor cells 2
Designed to give maximum drying area while taking up minimal bench space....
Used to remove wrinkles from sections and for reorientating embedded tissue....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: